Antiplatelet agents for preventing pre-eclampsia and its complications

Area of Science:

• Obstetrics and Gynecology
• Pharmacology
• Maternal-Fetal Medicine

Background:

• Pre-eclampsia is linked to an imbalance in prostacyclin and thromboxane production.
• This imbalance suggests that antiplatelet agents may prevent or delay pre-eclampsia.

Purpose of the Study:

• To evaluate the effectiveness and safety of antiplatelet agents for preventing pre-eclampsia in at-risk pregnant women.

Main Methods:

• A systematic review and meta-analysis of 51 randomized controlled trials involving 36,500 women.
• Searched multiple databases including Cochrane Pregnancy and Childbirth Group trials register, Cochrane Central Register of Controlled Trials, and EMBASE.

Main Results:

• Antiplatelet agents reduced the risk of pre-eclampsia by 19% (NNT 69).
• A 16% reduction in fetal or neonatal deaths was observed (NNT 227).
• Small reductions in preterm birth (7%) and small-for-gestational age babies (8%) were also noted.

Conclusions:

• Antiplatelet agents, primarily low-dose aspirin, offer moderate benefits in preventing pre-eclampsia.
• More research is needed to identify optimal patient selection, treatment timing, and dosage.